Melanocortin Receptor Agonist class drugs

1 result
Palatin Technologies
Usage: VYLEESI is indicated for treating premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) causing significant distress, not attributable to medical/psychiatric conditions, relationship issues, or substance effects. It is not approved for postmenopausal women or men and does not enhance sexual performance.